A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1

Journal of Viral Hepatitis

Volumn 22, Issue 8, 2015, Pages 658-664

  Tatum, H ^a   Thuluvath, P J ^b   Lawitz, E ^c   Martorell, C ^d   Demicco, M ^e   Cohen, S ^f   Rustgi, V ^g   Ravendhran, N ^h   Ghalib, R ⁱ   Hanson, J ^j   Zamparo, J ^k   Zhao, J ^k   Cooney, E ^k   Treitel, M ^k   Hughes, E ^k  

^a Options Health Research   (United States)

^b MERCY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d Research Institute   (United States)

^e Advanced Clinical Research Institute   (United States)

^f UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^g Metropolitan Research   (United States)

^h Digestive Disease Associates   (United States)

ⁱ Texas Clinical Research Institute   (United States)

^j Charlotte Gastroenterology and Hepatology   (United States)

^k BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

all oral regimen; direct acting antiviral; IL28B non CC; NS5B polymerase inhibitor; triple therapy

Indexed keywords

BECLABUVIR; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; VIRUS RNA; 8-CYCLOHEXYL-N-((DIMETHYLAMINO)SULFONYL)-1,1A,2,12B-TETRAHYDRO-11-METHOXY-1A-((3-METHYL-3,8-DIAZABICYCLO(3.2.1)OCT-8-YL)CARBONYL)CYCLOPROP(D)INDOLO(2,1-A)(2)BENZAZEPINE-5-CARBOXAMIDE; ALPHA INTERFERON; ANTIVIRUS AGENT; BENZAZEPINE DERIVATIVE; INDOLE DERIVATIVE; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADULT; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CHILL; CHRONIC HEPATITIS C; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DEPRESSION; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HYPERBILIRUBINEMIA; INSOMNIA; IRRITABILITY; LEUKOPENIA; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXIC HEPATITIS; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; WEIGHT REDUCTION; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; CLASSIFICATION; COMBINATION DRUG THERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENZYMOLOGY; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; MIDDLE AGED; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADULT; ANTIVIRAL AGENTS; BENZAZEPINES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INDOLES; INTERFERON-ALPHA; MALE; MIDDLE AGED; PLACEBOS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS; YOUNG ADULT;

EID: 84934827901     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12372     Document Type: Article

References (21)

1. Lawitz E, Mangia A, Wyles D, et al,. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887.
2. Jacobson I, Dore GJ, Foster GR, et al,. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-1, a phase III trial. J Hepatol 2013; 58 (Suppl. 1): S574 [abstract 1425].
3. Manns M, Marcellin P, Fred Poordad FP, et al,. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a phase III trial. J Hepatol 2013; 58 (Suppl. 1): S568 [abstract 1413].
4. Dore GJ, Lawitz E, Hézode C, et al,. Daclatasvir combined with peginterferon alfa-2a and ribavirin for 12 or 16 weeks in patients with HCV genotype 2 or 3 infection: COMMAND GT2/3 study. J Hepatol 2013; 58 (Suppl. 1): S570-S571 [abstract 1418].
5. Hezode C, Hirschfield G, Ghesquiere W, et al,. Randomized study of daclatasvir plus peginterferon alfa-2a and ribavirin for previously untreated chronic hepatitis C. Gut 2014; Jul 30. doi: 10.1136/gutjnl-2014-307498. [Epub ahead of print] PMID: 25080450
6. Lawitz E, Ghalib R, Rodriguez-Torres M,. COSMOS Study: SVR4 results of a once daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 null responders. 20th Conference on Retroviruses and Opportunistic Infections; March 3-6, 2013: Atlanta, GA [Abstract 155LB].
7. American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Recommendations for Testing, Managing, and Treating Hepatitis C, 2014. Available at: http://www.hcvguidelines.org/full-report-view (accessed 20 October 2014).
8. ™ (simeprevir) receives marketing authorisation in the European Union for the treatment of adults with hepatitis C genotype 1 and 4 infection. May 16, 2014. Available at: https://www.jnj.com/news/all/OLYSIO-simeprevir-receives-marketing-authorisation-in-the-European-Union-for-the-treatment-of-adults-with-hepatitis-C-genotype-1-and-4-infection (accessed 20 October 2014).
9. Bristol-Myers Squibb. Press release, European Commission approves Bristol-Myers Squibb's Daklinza (daclatasvir) across multiple genotypes for the treatment of chronic hepatitis C infection. August 27, 2014. Available at: http://news.bms.com/press-release/rd-news/european-commission-approves-bristol-myers-squibbs-daklinza-daclatasvir-across (acces-sed 20 October 2014).
10. ® (asunaprevir) dual regimen. July 7, 2014. Available at: http://news.bms.com/press-release/japan-approves-first-all-oral-interferon-and-ribavirin-free-hepatitis-c-treatment-dakl (accessed 20 October 2014).
11. Lemm JA, Liu M, Gentles RG, et al,. Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother 2014; 58: 3485-3495.
12. Karen S, Lemm J, Eley T, et al,. A randomized, placebo-controlled, single ascending dose study of BMS-791325, a hepatitis C virus NS5B polymerase inhibitor, in genotype 1 infection. Antimicrob Agents Chemother 2014; 58: 3496-3503.
13. McHutchison JG, Everson GT, Gordon SC, et al,. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838.
14. Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
15. Poordad F, Bronowicki JP, Gordon SC, et al,. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012; 143: 608-618.
16. Ge D, Fellay J, Thompson AJ, et al,. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
17. Kukolj G, McGibbon GA, McKercher G, et al,. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. J Biol Chem 2005; 280: 39260-39267.
18. Pelosi LA, Voss S, Liu M, Gao M, Lemm JA,. Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir. Antimicrob Agents Chemother 2012; 56: 5230-5239.
19. Bronowicki JP, Pol S, Thuluvath PJ, et al,. Randomized study of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 chronic hepatitis C. Antivir Ther 2013; 18: 885-893.
20. Everson GT, Sims KD, Rodriguez-Torres M, et al,. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 2014; 146: 420-429.
21. Everson GT, Sims KD, Thuluvath PJ, et al,. Phase 2b study of the interferon-free and ribavirin-free combination of daclatasvir, asunaprevir, and BMS-791325 for 12 weeks in treatment-naive patients with chronic HCV genotype 1 infection. 64th Annual Meeting of the American Association for the Study of Liver Diseases. November 1-5, 2013: Washington, DC [abstractLB-1].